[
  {
    "ts": null,
    "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
    "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
    "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757962258,
      "headline": "How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse",
      "id": 136767795,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1428756484/image_1428756484.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.",
      "url": "https://finnhub.io/api/news?id=3fda982920f1032e55bb136613c930653f13eefc81993eba7c6f23654858d182"
    }
  },
  {
    "ts": null,
    "headline": "Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test",
    "summary": "PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the f",
    "url": "https://finnhub.io/api/news?id=db4d39c04742138ee8187ffaafa22c992d33d9ad5ebc5015f9bf679cbf1c7811",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944800,
      "headline": "Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test",
      "id": 136749697,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the f",
      "url": "https://finnhub.io/api/news?id=db4d39c04742138ee8187ffaafa22c992d33d9ad5ebc5015f9bf679cbf1c7811"
    }
  },
  {
    "ts": null,
    "headline": "Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma",
    "summary": "First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (\"Perspective\" or the \"Company\") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted",
    "url": "https://finnhub.io/api/news?id=713572037bb7cc7be21fb5c3d5f83473032e70862dfc9372c3e2826b4a820cb6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937600,
      "headline": "Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma",
      "id": 136749698,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (\"Perspective\" or the \"Company\") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted",
      "url": "https://finnhub.io/api/news?id=713572037bb7cc7be21fb5c3d5f83473032e70862dfc9372c3e2826b4a820cb6"
    }
  },
  {
    "ts": null,
    "headline": "How Bad Is This Sector’s Health Scare?",
    "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
    "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757937307,
      "headline": "How Bad Is This Sector’s Health Scare?",
      "id": 136749580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Do not buy healthcare fund if you are allergic to any of its ingredients.  After a rough stretch, some investors were prepared to ignore the warning label and bet on the beaten-down sector this year.  For example, asset manager Janus Henderson pointed out in January that an index of health stocks had trailed the S&P 500 by an unprecedented 53 percentage points over two years and looked “deeply undervalued.”",
      "url": "https://finnhub.io/api/news?id=d5663078b0da748d9babef929632922dd1f67a4f1946b313e0d7952904a431f3"
    }
  }
]